JP2024518685A5 - - Google Patents

Info

Publication number
JP2024518685A5
JP2024518685A5 JP2023560623A JP2023560623A JP2024518685A5 JP 2024518685 A5 JP2024518685 A5 JP 2024518685A5 JP 2023560623 A JP2023560623 A JP 2023560623A JP 2023560623 A JP2023560623 A JP 2023560623A JP 2024518685 A5 JP2024518685 A5 JP 2024518685A5
Authority
JP
Japan
Prior art keywords
salt
cancer
compound
dose
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023560623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518685A (ja
JP7839803B2 (ja
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/058283 external-priority patent/WO2022207646A1/en
Publication of JP2024518685A publication Critical patent/JP2024518685A/ja
Publication of JP2024518685A5 publication Critical patent/JP2024518685A5/ja
Application granted granted Critical
Publication of JP7839803B2 publication Critical patent/JP7839803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023560623A 2021-03-29 2022-03-29 治療レジメンで使用するためのpi3k-デルタ阻害剤 Active JP7839803B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2104416.9 2021-03-29
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
GB2117511.2 2021-12-03
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (3)

Publication Number Publication Date
JP2024518685A JP2024518685A (ja) 2024-05-02
JP2024518685A5 true JP2024518685A5 (cg-RX-API-DMAC7.html) 2025-04-04
JP7839803B2 JP7839803B2 (ja) 2026-04-02

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560623A Active JP7839803B2 (ja) 2021-03-29 2022-03-29 治療レジメンで使用するためのpi3k-デルタ阻害剤

Country Status (17)

Country Link
US (2) US12605389B2 (cg-RX-API-DMAC7.html)
EP (2) EP4313058B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839803B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022251843B2 (cg-RX-API-DMAC7.html)
CA (1) CA3212731A1 (cg-RX-API-DMAC7.html)
DK (1) DK4313058T3 (cg-RX-API-DMAC7.html)
ES (1) ES3031295T3 (cg-RX-API-DMAC7.html)
FI (1) FI4313058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250516T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071610T2 (cg-RX-API-DMAC7.html)
LT (1) LT4313058T (cg-RX-API-DMAC7.html)
MX (1) MX2023011442A (cg-RX-API-DMAC7.html)
PL (1) PL4313058T3 (cg-RX-API-DMAC7.html)
PT (1) PT4313058T (cg-RX-API-DMAC7.html)
RS (1) RS66754B1 (cg-RX-API-DMAC7.html)
SI (1) SI4313058T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022207646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184266A1 (en) * 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005518A (es) 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Similar Documents

Publication Publication Date Title
US10590079B2 (en) Cyano-substituted indoles as LSD1 inhibitors
JP5546717B2 (ja) アリピプラゾール結晶質形態を調製する方法
JP5925394B2 (ja) 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
JP7558334B2 (ja) PI3K-γ阻害剤としてのアミノピラジンジオール化合物
US11225486B2 (en) Tertiary alcohols as PI3K-γ inhibitors
WO2020239097A1 (zh) 一种parp抑制剂微丸制剂及其制备工艺
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
JP6457658B2 (ja) 安定した、溶媒和物が含まれないアプレミラスト結晶形ii、及びその製造方法
CN110573500A (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
CA2957466C (en) Drug combinations to treat multiple myeloma
CN103221411B (zh) (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
CA2693390A1 (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
JP2021513973A (ja) ピリジン誘導体およびhiv感染を処置するためのその使用
FI4313058T3 (fi) Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon
JP2011518786A (ja) 調製及び使用のための組成物及び方法
JP2022540421A5 (cg-RX-API-DMAC7.html)
JP2018531288A5 (cg-RX-API-DMAC7.html)
JP2013544239A5 (cg-RX-API-DMAC7.html)
JP2021505575A (ja) 非ラセミ混合物およびその使用
JP5860895B2 (ja) 5−メチル−1−(ナフタレン−2−イル)−1h−ピラゾール誘導体
JP2018529742A5 (cg-RX-API-DMAC7.html)
SG11202108909SA (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
JP2022169780A5 (cg-RX-API-DMAC7.html)
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
WO2025149082A1 (zh) 取代桥环类抑制剂及其制备方法和应用